icon star paper   News Update  
Back grey_arrow_rt.gif
Multivitamins May Slow Progression of HIV for Patients in Earliest Phase of Disease, Study Says
  HIV-positive women who take a multivitamin once daily are 30% less likely than those who do not take the supplements to progress to the latest stage of HIV, according to a study published in the July 1 issue of the New England Journal of Medicine, the Boston Globe reports (Smith, Boston Globe, 7/1). Researchers from Harvard University School of Public Health and Muhimbili University College of Health Sciences in Tanzania between 1995 and 2003 studied 1,078 pregnant HIV-positive women in Dar es Salaam, Tanzania, who did not have access to antiretroviral treatment (McNeil, New York Times, 7/1). Researchers randomly assigned participants to receive a multivitamin, a multivitamin with vitamin A, vitamin A alone or a placebo (Nano, AP/Long Island Newsday, 6/30). The multivitamins contained about three times the recommended daily allowance of vitamin E and six to 10 times the allowance of vitamins C and B-complex, according to the Times (New York Times, 7/1). Participants in the study, which was funded by the National Institute of Child Health and Human Development, took the vitamins during pregnancy and for the duration of the study, according to a NICHHD release. All of the participants received folic acid and an iron supplement during pregnancy, regardless of whether they received placebos or vitamins.
Measures, Changes in Method
Participants received periodic checkups for four years after delivering their infants and about 50% of the participants received checkups for more than five years after delivering. Researchers monitored participants to determine if the supplements affected the progression of HIV to severe symptoms, AIDS or death, according to the release. Researchers also examined the effect of the supplements on CD4+ cells and CD8+ cells and on viral load (NICHHD release, 6/30). Dr. Wafaie Fawzi, a professor of nutrition and epidemiology at Harvard and lead author of the study, said that the study was modified twice for ethical reasons, according to the Times. First, researchers removed vitamin A from the regimen because of evidence demonstrating an increased risk of mother-to-child HIV transmission. Second, researchers placed all participants on multivitamins until they delivered due to evidence that the vitamins prevented fetal death and premature birth, the Times reports. After the women delivered, the researchers put them back on their previous regimens, according to the Times (New York Times, 7/1).
Findings, Implications
The findings show that although the benefits of multivitamins are statistically significant, the results were not "dramatic," according to Reuters (Emery, Reuters, 6/30). Researchers found that 67 of the 271 participants who received multivitamins progressed to an advanced stage of disease, which the World Health Organization classifies as stage 4, or they died; compared with 83 of the 267 women in the placebo group (Fawzi et al., NEJM, 7/1). Researchers also found that although the number of deaths was lower in the multivitamin group, the finding was not statistically significant. In addition, women taking multivitamins had fewer symptoms associated with later-stage HIV -- including mouth infections, mouth ulcers or diarrheal diseases -- than those in the placebo group. Researchers also found that women receiving multivitamins had CD4+ cell counts an average of 48 cells higher than the CD4+ cell counts of those in the placebo group; viral load was also "modestly but significantly lower" in women receiving multivitamins, according to the NICHHD release (NICHHD release, 6/30). Fawzi said that although men were not included in the study, the benefits of multivitamins likely would apply to them, according to the AP/Newsday (AP/Long Island Newsday, 6/30). >>


Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
  icon paper stack View Older Articles   Back to Top   www.natap.org